These 2 Growth Stocks Are Easily Defying the Bear Market
Even if it isn't a good idea to fixate on how your investments perform on a month-to-month basis, it's always a plus when your stocks can shrug off the detrimental impact of a bear market. And with the market falling back sharply during the past 12 months amid rising economic instability, that's no idle concern right now.
But some growth stocks aren't having any problem with doing business as usual, and are positioned to keep laughing in the face of a wider decline. Let's look at two of the most promising candidates.
Wall Street analysts are estimating that AbbVie's (NYSE: ABBV) revenue will contract both this year and next year owing to generic competition to its hit medicine, Humira. Losing market share with Humira means that the top line will potentially fall to reach roughly $53 billion, a decline of around $5 billion from its total sales in 2022. Nonetheless, AbbVie's shares are powering along as always, with their total return increasing by more than 12.4% since mid-February of 2022 -- unusually strong performance for a company that's anticipated to make less money in the near future than it does today.
Source Fool.com
